(DBXS) Switzerland - Overview
Etf: Swiss Equities, ETF, Morningstar Index
Dividends
| Dividend Yield | 1.67% |
| Yield on Cost 5y | 2.23% |
| Yield CAGR 5y | 8.98% |
| Payout Consistency | 92.1% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 11.2% |
| Relative Tail Risk | 0.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | 6.17 |
| Character TTM | |
|---|---|
| Beta | 0.043 |
| Beta Downside | 0.166 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.75% |
| CAGR/Max DD | 0.56 |
Description: DBXS Switzerland January 31, 2026
The Xtrackers Switzerland UCITS ETF (ticker DBXS, listed on XETRA) is a Germany-domiciled fund that aims to replicate the Morningstar Switzerland Total Market Index (TME NR CHF). It belongs to the “Switzerland Equity” ETF category and offers investors exposure to the broad Swiss equity market in Swiss francs.
As of 30 Nov 2025, DBXS reported net assets of roughly CHF 2.1 billion, an ongoing expense ratio of 0.20 % and a 30-day SEC yield of 2.1 % (annualized). The fund’s top five holdings were Nestlé (~9 %), Novartis (~7 %), Roche (~6 %), UBS (~5 %) and Zurich Insurance (~4 %). Sector allocation was dominated by Health Care (≈38 %) and Financials (≈30 %), reflecting the composition of the underlying index.
Key drivers for DBXS’s performance include Swiss GDP growth (forecast at 1.2 % YoY for 2025), the strength of the CHF relative to the euro (which can affect export-oriented earnings), and sector-specific trends such as continued demand for pharmaceuticals and the stability of the domestic banking system. A tracking error of 0.12 % over the past 12 months suggests the ETF closely follows its benchmark.
For a deeper, data-rich analysis of how these factors may evolve, you might want to explore the ValueRay platform.
What is the price of DBXS shares?
Over the past week, the price has changed by +0.91%, over one month by +2.49%, over three months by +10.31% and over the past year by +10.30%.
Is DBXS a buy, sell or hold?
What are the forecasts/targets for the DBXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 164.2 | 8.6% |
DBXS Fundamental Data Overview February 09, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.58b EUR (1.58b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.58b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.58b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.07% (E(1.58b)/V(1.58b) * Re(6.07%) + (debt-free company))
Discount Rate = 6.07% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)